Pricing Log in Create free account
Sunday 8 November 2026 Export GRFS’s income statement to Excel — free account

Grifols, S.A.

GRFS

Healthcare Drug Manufacturers General

Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.

Revenue
+9.37%
EPS
+59.8%
Free cash flow
+4.11%
Total debt
−6.08%

Quarter to September 2026, against a year earlier

8.43 0.03 −0.35%
Market cap
$2.2B
P/E
18.2×
Fwd P/E
—
Dividend yield
1.12%
F-score
5/9
ROIC
4.76%
Net debt / EBITDA
5.2×
Dividend safety
54/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Grifols, S.A. (GRFS) EV/EBITDA

Alert me on EV/EBITDA

As of 6 November 2026, Grifols, S.A. (GRFS) trades at a EV/EBITDA of 8.4×. Over the past ten years it has ranged from 7.7× (July 2026) to 17.3× (April 2015); the current reading is higher than 12% of that period. That is below the Drug Manufacturers General industry median of 14.7× and in line with the Healthcare sector median of 8.5×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 8.5× (18.50%)
FY2024 10.4× 31.54%
FY2023 7.9× (23.93%)
FY2022 10.4× 11.99%
FY2022 9.3× 0.83%
FY2021 9.2× (32.13%)
FY2021 13.6× 1.71%
FY2020 13.4× (9.60%)
FY2020 14.8× 1.00%
FY2019 14.7× 4.07%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 8.0× (2.99%)
Mar 2026 8.2× (3.26%)
Dec 2025 8.5× (11.46%)
Sep 2025 9.6× (3.29%)
29 more quarters

Against its own ten years

Low 7.7× High 17.3×
Ten-year median 12.5×
Current reading's percentile 12

EV/EBITDA against peers

Company EV/EBITDA
NSRX Nasus Pharma Ltd. compare n/m
AMRN Amarin Corporation PLC compare 2.2×
NVO Novo Nordisk A/S compare 7.0×
OGN Organon & Co. compare 7.5×
GRFS Grifols, S.A. 8.4×
GSK GSK PLC Sponsored ADR compare 10.5×
BMY Bristol Myers Squibb Company compare 11.1×
SNY Sanofi compare 11.4×
BIIB Biogen Inc. compare 18.7×
Drug Manufacturers General industry median 14.7×
Healthcare sector median 8.5×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on GRFS